ClinicalTrials.gg
CompletedNCT01003015Updated Apr 3, 2015

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

A Phase 2 interventional study of BAY73-4506 in Carcinoma, Hepatocellular, sponsored by Bayer. Completed at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-03.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing regorafenib in Carcinoma, Hepatocellular — 7 open to participants now, 9 under way, none of them phase 3. regorafenib · Carcinoma, Hepatocellular.

Enrollment
11th of 22
36 · median 33
Started
2009
the only one that year
Phase 2
16 of 22
6 open now
Registered
1st of 22
by date
Lead sponsor
5 of 22
Bayer

Among the 22 studies testing regorafenib in Carcinoma, Hepatocellular, this one is the 11th largest by enrollment, is the only one that started in 2009, is one of 16 in phase 2, and was the 1st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 22 studies testing regorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing regorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.

03

Conditions studied

  • Carcinoma, Hepatocellular

Keywords

  • HCC
  • Safety
  • BAY73-4506
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged equal or above 18 years.
  • BCLC stage Category A, B or C that cannot benefit from treatments of established efficacy with higher priority such as resection, liver transplantation, local ablation, chemoembolization or systemic sorafenib.
  • Liver function status class A.
  • Failure to prior treatment with sorafenib (defined as radiological progression under sorafenib therapy)
  • Local or loco-regional therapy (eg, surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed = 4 weeks before first dose of BAY73-4506.
  • PS of 0 or 1.
  • Adequate bone marrow, liver and renal function

Exclusion criteria

Exclusion Criteria:

  • Prior systemic treatment with molecular targeted agents for HCC, except sorafenib. Prior chemotherapy treatment is allowed.
  • Known history or symptomatic brain or meningeal tumors (head CT or MRI at screening to confirm the absence of central nervous system [CNS] disease if patient has symptoms suggestive or consistent with CNS disease).
  • Congestive heart failure >/= class 2
  • Unstable angina (angina symptoms at rest, new onset angina within the last 3 months) or myocardial infarction (MI) within the past 6 months before start of study medication.
  • Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
  • Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including ), deep vein thrombosis or pulmonary embolism within 6 months before the start of study treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: BAY73-4506

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event Collection

    Time frame: Up to 30+/- 7 days after permanently discontinuing BAY73-4506 administration

Secondary outcomes

  1. Time to progression

    Time frame: Every 6 weeks during treatment and after 6 cycle treatment every 18 weeks till progression

  2. Objective response rate

    Time frame: Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression

  3. Disease control rate

    Time frame: Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression

  4. Overall survival

    Time frame: Every 6 weeks during treatmen and after 6 cycle treatment every 18 weeks till progression

  5. Trough concentration of Regorafenib and metabolites (for Europe only)

    Time frame: Cycle 1 Day 15 and Cycle 2 Day 1

  6. Full Pharmacokinetics profile of BAY73-4506 and metabolites (for Korea only)

    Time frame: Cycle 1 Day 21 to Day 28

07

Study locations

13 sites
  • Regensburg, Bayern 93042, Germany
  • Frankfurt, Hessen 60590, Germany
  • Essen, Nordrhein-Westfalen 45122, Germany
  • Mainz, Rheinland-Pfalz 55131, Germany
  • Magdeburg, Sachsen-Anhalt 39112, Germany
  • Rozzano, Milano 20089, Italy
  • Bologna, 40138, Italy
  • Milano, 20122, Italy
  • Milano, 20133, Italy
  • Roma, 00168, Italy
  • Daegu, 700-721, Korea, Republic of
  • Seoul, 135-710, Korea, Republic of
  • Barcelona, 08036, Spain
08

References and documents

Publications

  • Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25. PubMed 23809766 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Nov 2010 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2009
First posted
Oct 28, 2009
Start
Sep 2009
Primary completionActual
Nov 2010
CompletionActual
Mar 2013
Last update
Apr 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01003015
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 28, 2009
Start date
Sep 2009
Primary completion
Nov 2010
Completion
Mar 2013
Last update
Apr 3, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion